These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11367260)

  • 21. A new approach to initial antiretroviral therapy: protease-sparing combination regimens.
    Hanna L
    BETA; 1998 Oct; ():9-13. PubMed ID: 11365999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of potential clinically significant drug interactions in HIV-infected patients: a comprehensive therapeutic approach.
    Iniesta-Navalón C; Franco-Miguel JJ; Gascón-Cánovas JJ; Rentero-Redondo L
    HIV Med; 2015 May; 16(5):273-9. PubMed ID: 25523089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacology: a progress report.
    Flexner C
    Hopkins HIV Rep; 1999 Mar; 11(2):13-4, 16. PubMed ID: 11366246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review.
    Hansen BR; Haugaard SB; Iversen J; Nielsen JO; Andersen O
    Scand J Infect Dis; 2004; 36(4):244-53. PubMed ID: 15198179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selected highlights from the 5th Conference on Retroviruses and Opportunistic Infections.
    Bartnof HS
    BETA; 1998 Apr; ():49-56. PubMed ID: 11365269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug reactions & lipodystrophy workshop.
    Coppedge B
    STEP Perspect; 1999; 99(3):17-8. PubMed ID: 11366865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonnucleoside reverse transcriptase inhibitors.
    Murphy RL
    AIDS Clin Care; 1997 Oct; 9(10):75-7, 79. PubMed ID: 11364757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Switch strategy: replacing the protease inhibitor. Quality of life improves].
    MMW Fortschr Med; 2000; 142(3 Suppl):37. PubMed ID: 11012292
    [No Abstract]   [Full Text] [Related]  

  • 29. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simplifying suppression: switching therapies to improve HIV disease management.
    Moyle GJ
    AIDS Read; 2004 Jul; 14(7):380-4. PubMed ID: 15282867
    [No Abstract]   [Full Text] [Related]  

  • 31. Risks and synergies from drug interactions.
    Sahai J
    AIDS; 1996 Nov; 10 Suppl 1():S21-5. PubMed ID: 8970672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. After the drugs: what's next?
    Schouten JT
    Res Initiat Treat Action; 1998 Dec; 4(7):9-10. PubMed ID: 11366085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efavirenz's complications.
    GMHC Treat Issues; 1998 May; 12(5):6. PubMed ID: 11365477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cohort studies: what do they tell us?
    Chêne G
    J HIV Ther; 2001 May; 6(2):28-31. PubMed ID: 11501200
    [No Abstract]   [Full Text] [Related]  

  • 35. New treatment options.
    Fornataro K; Jefferys R
    Body Posit; 1999 Jun; 12(6):11-2. PubMed ID: 11367013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-HIV agents. Leading to lipodystrophy.
    TreatmentUpdate; 2007 Feb; 19(2):3-4. PubMed ID: 17447312
    [No Abstract]   [Full Text] [Related]  

  • 37. Anti-HIV agents. A second study confirms fat loss issues with efavirenz.
    TreatmentUpdate; 2007 Feb; 19(2):6-7. PubMed ID: 17447314
    [No Abstract]   [Full Text] [Related]  

  • 38. Antiviral therapy: how simple can you get?
    Gilden D
    GMHC Treat Issues; 1998 Nov; 12(11):3-7. PubMed ID: 11365906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are changes in body shape due to drug side effects?
    TreatmentUpdate; 1999 Jun; 11(4):3-4. PubMed ID: 11366790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors.
    Introcaso CE; Hines JM; Kovarik CL
    J Am Acad Dermatol; 2010 Oct; 63(4):549-61; quiz 561-2. PubMed ID: 20846563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.